Zimmer Biomet's (ZBH) move to acquire LDR Holding (LDRH) is a smart one and it also bodes well for another medical device company NuVasive (NUVA) , said TheStreet's Jim Cramer. Zimmer Biomet announced Tuesday that it has agreed to buy LDR Holding for roughly $1 billion. Zimmer offered $37 a share for each of the medical-device company's shares outstanding, a 64 percent premium to Monday's close. The deal is expected to close in the third quarter. Cramer said NuVasive is 'the obvious play so go buy it.'
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.